LAUSR

OBJECTIVE To evaluate whether septic shock patients with pulmonary infection and life-threatening hypoxemia can benefit from V-V ECMO. METHODS Retrospective clinical data analysis on patients who suffered septic shock with pulmonary infection, categorized into V-V ECMO and control groups.The propensity score matching (PSM) method was used to screen patients matched for age, gender, and disease severity.The primary outcome was 30- and 90-day mortality after diagnosis of septic shock. RESULTS After PSM, 31 pairs of patients were enrolled in this study, and there were no significant differences between the two groups in terms of gender, age, chronic disease, Acute Physiological and Chronic Health Evaluation II (APACHE II) score, and Sequential Organ Failure Assessment (SOFA) score. Within 28 days after the diagnosis of septic shock, the median time of renal replacement therapy-free days was longer in the V-V ECMO group than in the control group (27 days versus 9 days ; P=0.044).Kaplan-Meier analysis showed that 30-day mortality was lower in the V-V ECMO group than in the control group (38.7% versus 61.3%; HR 0.488; 95% CI 0.240-0.992; P=0.043，by Log-rank test); 90-day mortality was not significantly different between the two groups (51.6% versus 67.7%; P=0.097). CONCLUSION Patients receiving V-V ECMO support had lower 30-day mortality and faster recovery of renal function within 28 days compared with those receiving conventional therapy. However, V-V ECMO did not improve 90-day survival in septic shock patients with pulmonary infection.